Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by persistent differences in social communication and interaction, alongside restricted or repetitive patterns of behavior, interests, or activities.
New genomic studies show a practical recall-by-genotype strategy for psychiatry, shared genetic liability across psychiatric and physical conditions, and improved disease prediction using disease-history trajectories.
Adia Med has submitted an IRB study of AdiaVita for lower back pain and launched a redesigned website. The placebo-controlled crossover trial will enroll about 100 participants; an ASD study is also recruiting.
Transcripta Bio raised $24M backed by Mayo Clinic and Omnimed for AI-driven neurological and neuromuscular therapies. The funds will support IND-enabling studies and clinical preparation for ASD and FSHD programs.
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
In vivo base editing corrected the CHD3 p.R1025W mutation in a mouse model of Snijders Blok–Campeau syndrome, restoring protein levels and rescuing behavioural abnormalities. Intrathecal AAV delivery in nonhuman primates supported translational feasibility.
A study of nearly 70,000 children found girls exposed to SARS-CoV-2 infection in utero had a 44% increased risk of autism spectrum disorder. The research showed 3.97% of pregnant women had COVID-19 infection, with most cases occurring in the third trimester. No increased risk was observed for boys or for speech/language and motor delays overall.
Scientists developed Ribo-STAMP technology to map protein production across nearly 20,000 individual mouse brain cells, revealing unexpected differences in how memory neurons translate proteins and potential insights into neurological disorders.
The U.S. Food and Drug Administration has approved an Investigational New Drug application for FRF-001, a viral gene therapy for FOXG1 syndrome developed at the University at Buffalo. The first-in-human trial will be independently sponsored by the FOXG1 Research Foundation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779525 |
Movement-Based Digital Game Intervention for Children With Autism Spectrum Disorder |
COMPLETED | NA |
| NCT07775937 |
Social Robots and Board Games for Children With Autism Spectrum Disorder |
RECRUITING | NA |
| NCT07770867 |
Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD |
NOT_YET_RECRUITING | NA |
| NCT07770451 |
Medial Prefrontal Cortex Brain Magnetic Stimulation in Autism |
NOT_YET_RECRUITING | NA |
| NCT07770152 |
Semaglutide in Youth With Autism Spectrum Disorder |
NOT_YET_RECRUITING | PHASE4 |
| NCT07765277 |
The Effect of Exergame-Supported Training on Reaction Time and Agility |
COMPLETED | NA |
| NCT07763067 |
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young Autistic Children |
COMPLETED | NA |
| NCT07758088 |
Dance, Yoga, And Mindful Movement Training For ASD |
NOT_YET_RECRUITING | NA |
| NCT07757295 |
Effectiveness of an Online Psychological Support Program for Mothers of Children With Autism |
COMPLETED | NA |
| NCT07757035 |
Effects of Low Frequency Whole Body Vibrations on Motor Skills and Sensory Integration in Children With Autism |
COMPLETED | NA |
